Valproic acid increased the efficacy of EGFR TKIs on EGFR/TP53 co‐mutated lung cancers and downregulated mutant‐p53 levels
出版年份 2023 全文链接
标题
Valproic acid increased the efficacy of EGFR TKIs on EGFR/TP53 co‐mutated lung cancers and downregulated mutant‐p53 levels
作者
关键词
-
出版物
MOLECULAR CARCINOGENESIS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-10-25
DOI
10.1002/mc.23651
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
- (2023) Haiyan Sun et al. BMC CANCER
- Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma
- (2022) Natalie I. Vokes et al. Journal of Thoracic Oncology
- Impact of TP53 mutations on EGFR-tyrosine kinase inhibitor efficacy and potential treatment strategy
- (2022) Jing Fu et al. Clinical Lung Cancer
- Drugging p53 in cancer: one protein, many targets
- (2022) Ori Hassin et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation
- (2022) Kai Shang et al. BMC CANCER
- Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
- (2022) Kai Fu et al. Journal of Hematology & Oncology
- Hidden pharmacological activities of valproic acid: A new insight
- (2021) Dhirendra Singh et al. BIOMEDICINE & PHARMACOTHERAPY
- Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy
- (2020) Ling Li et al. Frontiers in Oncology
- Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
- (2020) Kang Qin et al. BMC CANCER
- Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)
- (2020) Xiang-Meng Li et al. Clinical Lung Cancer
- Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
- (2018) D Westover et al. ANNALS OF ONCOLOGY
- USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells
- (2018) Achuth Padmanabhan et al. Nature Communications
- Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
- (2015) E. M. Alexandrova et al. NATURE
- Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data
- (2015) H-W Cheng et al. Cell Death & Disease
- Chaperone-dependent stabilization and degradation of p53 mutants
- (2008) P Muller et al. ONCOGENE
- Dose translation from animal to human studies revisited
- (2007) Shannon Reagan-Shaw et al. FASEB JOURNAL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started